Staats Peter S, Markowitz Jeffrey, Schein Jeffrey
Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
South Med J. 2004 Feb;97(2):129-34. doi: 10.1097/01.SMJ.0000109215.54052.D8.
Opioid therapy plays a key role in the management of chronic pain. Constipation is one of the more frequently occurring adverse effects associated with opioid therapy.
A retrospective cohort design study was conducted to determine the incidence of constipation in chronic pain patients who received three different long-acting opioids (transdermal fentanyl, oxycodone HCl controlled-release [CR], or morphine CR) for malignant or nonmalignant chronic pain. The data source was claims data (January 1996 through March 2001) from a 20% random sample of the California Medicaid (Medi-Cal) database. Claims data were from adult patients with chronic pain (malignant or nonmalignant) who had no prior diagnosis of constipation and no prior usage of long-acting opioids for at least 3 months before the observation period. Patients were followed for at least 3 months after the initiation of opioid therapy. ICD-9 code for diagnosis of constipation was the main outcome variable. Crude rates of constipation, annual incidence density, relative risk, and adjusted odds ratios were compared.
A total of 1,836 patients (601 receiving transdermal fentanyl, 721 receiving oxycodone CR, and 514 receiving morphine CR) were included in the analysis. Crude (unadjusted) rates of constipation were 3.7% for transdermal fentanyl, 6.1% for oxycodone CR, and 5.1% for morphine CR (P > 0.05). Transdermal fentanyl had a lower annual incidence density and risk of constipation than oxycodone CR and morphine CR (P > 0.05). After adjusting for confounding variables, including race and supplemental opioid use, the adjusted risk of constipation was 78% greater in the oxycodone CR group (P = 0.0337) and 44% greater in the morphine CR group (P = 0.2242) than in the transdermal fentanyl group.
In this population, patients receiving transdermal fentanyl had a lower risk of developing constipation compared with those receiving oxycodone CR or morphine CR.
阿片类药物疗法在慢性疼痛管理中起着关键作用。便秘是与阿片类药物疗法相关的较常见不良反应之一。
进行了一项回顾性队列设计研究,以确定接受三种不同长效阿片类药物(透皮芬太尼、盐酸羟考酮控释片[CR]或吗啡CR)治疗恶性或非恶性慢性疼痛的慢性疼痛患者中便秘的发生率。数据来源是加利福尼亚医疗补助(医保)数据库20%随机样本的理赔数据(1996年1月至2001年3月)。理赔数据来自患有慢性疼痛(恶性或非恶性)且在观察期前至少3个月没有便秘既往诊断且未使用过长效阿片类药物的成年患者。患者在开始阿片类药物治疗后至少随访3个月。便秘诊断的国际疾病分类第九版(ICD-9)编码是主要结局变量。比较了便秘的粗发病率、年发病密度、相对风险和调整后的比值比。
共有1836例患者(601例接受透皮芬太尼,721例接受羟考酮CR,514例接受吗啡CR)纳入分析。透皮芬太尼的便秘粗(未调整)发病率为3.7%,羟考酮CR为6.1%,吗啡CR为5.1%(P>0.05)。透皮芬太尼的年发病密度和便秘风险低于羟考酮CR和吗啡CR(P>0.05)。在对包括种族和补充阿片类药物使用等混杂变量进行调整后,羟考酮CR组的便秘调整风险比透皮芬太尼组高78%(P = 0.0337),吗啡CR组比透皮芬太尼组高44%(P = 0.2242)。
在该人群中,与接受羟考酮CR或吗啡CR的患者相比,接受透皮芬太尼的患者发生便秘的风险较低。